Hjelmesaeth Jøran, Hofsø Dag, Aasheim Erlend T, Jenssen Trond, Moan Johan, Hager Helle, Røislien Jo, Bollerslev Jens
Morbid Obesity Center, Vestfold Hospital Trust, Health Region South, Tønsberg, Norway.
Cardiovasc Diabetol. 2009 Feb 3;8:7. doi: 10.1186/1475-2840-8-7.
The prevalence of vitamin D insufficiency and secondary hyperparathyroidism is high among morbidly obese subjects. Further, low serum levels of 25-hydroxyvitamin D (25 [OH]D) and magnesium have been associated with increased risk of the metabolic syndrome (MS), and recently, a possible link between PTH and MS has been reported. Although it is well known that the synthesis and secretion of PTH is regulated by serum levels of calcium, phosphate, magnesium and 25(OH)D, less is known about the possible clustered affiliation of these parameters with MS. We aimed to explore whether MS is associated with abnormal serum levels of PTH, 25(OH)D and magnesium in a population of morbidly obese patients.
Fasting serum levels of 25(OH)D, PTH and magnesium were assessed in a cross-sectional cohort study of 1,017 consecutive morbidly obese patients (68% women). Multiple logistic regression analyses were used to assess the independent effect of PTH, 25(OH)D and magnesium on the odds for MS (National Cholesterol Education Program [NCEP]) after adjustment for confounding factors.
Sixty-eight percent of the patients had MS. Patients with MS had lower mean serum magnesium (P < 0.001) and higher mean PTH (P = 0.067) than patients without MS, whereas mean 25(OH)D did not differ significantly. Patients with PTH levels in the second to fourth quartiles had higher odds of prevalent MS (odds ratio 1.47 [95% CI 0.92-2.35], 2.33 [95% CI 1.40-3.87] and 2.09 [95% CI 1.23-3.56], respectively), after adjustment for 25(OH)D, magnesium, calcium, phosphate, creatinine, age, gender, season of serum sampling, BMI, current smoking, albuminuria, CRP, insulin resistance and type 2 diabetes. Further, PTH was significantly correlated with systolic and diastolic pressure (both P < 0.001), but not with the other components of MS. The levels of 25(OH)D and magnesium were not associated with MS in the multivariate model.
The PTH level, but not the vitamin D level, is an independent predictor of MS in treatment seeking morbidly obese Caucasian women and men. Randomized controlled clinical trials, including different therapeutic strategies to lower PTH, e.g. calcium/vitamin D supplementation and weight reduction, are necessary to explore any cause-and-effect relationship.
病态肥胖患者中维生素D不足和继发性甲状旁腺功能亢进的患病率很高。此外,血清25-羟基维生素D(25[OH]D)和镁水平较低与代谢综合征(MS)风险增加相关,最近,有报道称甲状旁腺激素(PTH)与MS之间可能存在联系。虽然众所周知PTH的合成和分泌受血清钙、磷、镁和25(OH)D水平调节,但对于这些参数与MS可能的聚集关联了解较少。我们旨在探讨在病态肥胖患者群体中MS是否与PTH、25(OH)D和镁的血清水平异常有关。
在一项对1017例连续的病态肥胖患者(68%为女性)的横断面队列研究中,评估空腹血清25(OH)D、PTH和镁水平。在调整混杂因素后,使用多元逻辑回归分析评估PTH、25(OH)D和镁对MS(美国国家胆固醇教育计划[NCEP])发生几率的独立影响。
68%的患者患有MS。与无MS的患者相比,患有MS的患者平均血清镁水平较低(P<0.001),平均PTH水平较高(P=0.067),而平均25(OH)D水平无显著差异。在调整25(OH)D、镁钙、磷、肌酐、年龄、性别、血清采样季节、体重指数、当前吸烟情况、蛋白尿、C反应蛋白、胰岛素抵抗和2型糖尿病后,处于第二至第四四分位数的PTH水平患者患MS的几率更高(比值比分别为1.47[95%可信区间0.92-2.35]、2.33[95%可信区间1.40-3.87]和2.09[95%可信区间1.23-3.56])。此外,PTH与收缩压和舒张压均显著相关(均P<0.001),但与MS的其他组分无关。在多变量模型中,25(OH)D和镁水平与MS无关。
在寻求治疗的病态肥胖白种女性和男性中,PTH水平而非维生素D水平是MS的独立预测因素。需要进行随机对照临床试验,包括采用不同治疗策略降低PTH,如补充钙/维生素D和减轻体重,以探讨任何因果关系。